Primary Care/Hospitalist
RSSArticles
-
Glecaprevir and Pibrentasvir Tablets (Mavyret)
The FDA has approved a dual fixed-dose combination of glecaprevir, a NS3/4A protease inhibitor, and pibrentasvir, a NS5A inhibitor, for the treatment of all major genotypes (1-6) of chronic hepatitis C infections.
-
Genital HPV in Men: How Common Is It?
In this U.S. cross-sectional survey, the prevalence of genital human papillomavirus (HPV) infection in adult men was 45%, of which 25% were high-risk subtypes. The overall rate of HPV vaccination among those who were eligible was 11%.
-
Dual Antibiotic Therapy Is Not Routinely Necessary for Uncomplicated Cellulitis
A randomized, multicenter, placebo-controlled clinical trial that enrolled patients presenting to emergency departments with uncomplicated cellulitis found the addition of trimethoprim-sulfamethoxazole to cephalexin did not lead to better outcomes.
-
Is This 4:1 Flutter?
The rhythm in the figure was diagnosed as atrial flutter with 4:1 AV conduction. Do you agree? How would you confirm your answer?
-
Clinical Briefs
In this section: treating hypothyroidism in seniors; revisiting penicillin allergies; and new diverticulitis guidance.
-
Sofosbuvir, Velpatasvir, and Voxilaprevir Tablets (Vosevi)
Vosevi is indicated for the treatment of adult patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis who are infected with genotype 1, 2, 3, 4, 5, or 6, and have been treated previously with a hepatitis C regimen containing an NS5A inhibitor.
-
Eat Right, and Live
An improvement in diet over 12 years in middle-aged nurses and other health professionals resulted in a decreased risk of death.
-
Glucose Self-monitoring Not Helpful for Non-insulin-treated Type 2 Diabetes
In this pragmatic randomized trial, self-monitoring blood glucose did not lead to lower hemoglobin A1c levels or improvement in health-related quality-of-life measures.
-
Contraceptive Research: Science Heads to New Frontiers
Funding recently has been awarded to scientists around the globe through the Grand Challenges Explorations program, an initiative funded by the Bill & Melinda Gates Foundation. The program seeks to foster concepts for contraceptive discovery platforms that can contribute to the development of new methods suitable for women and men living in limited resource settings.
-
Increased Focus on Preventing Preeclampsia
Cases of preeclampsia in the United States have increased since 1980 from 2.4% of all pregnancies to 3.8% in 2010. This increase is cause for concern: Preeclampsia accounts for more than $2.18 billion of the healthcare expenditure in the first 12 months after birth.